We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

58 hedge funds and large institutions have $339M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

26% more funds holding

Funds holding: 46 → 58 (+12)

21% less capital invested

Capital invested by funds: $427M → $339M (-$87.9M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
58
Holders Change
+12
Holders Change %
+26.09%
% of All Funds
1.28%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
14
Increased
25
Reduced
10
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.72M
2
CI
Clal Insurance
Israel
+$4.57M
3
WP
Woodline Partners
California
+$4M
4
AG
Artal Group
Luxembourg
+$3.18M
5
QF
QVT Financial
New York
+$2.13M

Top Sellers

Rank Fund Capital Flow
1
OFM
Omega Fund Management
Massachusetts
-$6.3M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.14M
3
BI
BVF Inc
California
-$3.58M
4
RCM
RA Capital Management
Massachusetts
-$1.96M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$168M – – –
RCM
2
RA Capital Management
Massachusetts
$39.5M -$1.96M -123,071 -4%
EC
3
EcoR1 Capital
California
$27.4M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$14.3M +$28.9K +1,817 +0.2%
BlackRock
5
BlackRock
New York
$13.8M +$6.72M +422,205 +59%
BC
6
Boxer Capital
California
$13.7M – – –
Fidelity Investments
7
Fidelity Investments
Massachusetts
$9.61M -$1.33M -83,400 -10%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$6.05M – – –
BI
9
BVF Inc
California
$5.26M -$3.58M -225,000 -34%
Vanguard Group
10
Vanguard Group
Pennsylvania
$4.44M +$932K +58,602 +19%
CI
11
Clal Insurance
Israel
$3.56M +$4.57M +287,378 +6,218%
OFM
12
Omega Fund Management
Massachusetts
$3.33M -$6.3M -396,100 -59%
Bank of America
13
Bank of America
North Carolina
$3.15M -$295K -18,532 -7%
WP
14
Woodline Partners
California
$3.07M +$4M +251,532 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$2.75M +$186K +11,664 +5%
State Street
16
State Street
Massachusetts
$2.55M +$1.66M +104,629 +100%
AG
17
Artal Group
Luxembourg
$2.44M +$3.18M +200,000 New
Northern Trust
18
Northern Trust
Illinois
$1.91M +$1.2M +75,725 +93%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.89M +$894K +56,199 +57%
QF
20
QVT Financial
New York
$1.63M +$2.13M +133,690 New
Millennium Management
21
Millennium Management
New York
$1.18M +$1.54M +96,687 New
Renaissance Technologies
22
Renaissance Technologies
New York
$961K +$1.25M +78,805 New
Morgan Stanley
23
Morgan Stanley
New York
$937K +$1.02M +63,847 +493%
DCM
24
DAFNA Capital Management
California
$914K – – –
UBS Group
25
UBS Group
Switzerland
$908K -$35.4K -2,224 -3%
1
2 3

PRVL Hedge Fund Activity: Q1 2020 in Review

58 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q1 2020, worth a combined $339M — down 21% from $427M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PRVL positions and 2 closed out — a net gain of 12 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $6.72M. The largest seller was Omega Fund Management, cutting an estimated $6.3M.

  • 58 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q1 2020, up from 46 in Q4 2019.
  • Funds reported $339M of Prevail Therapeutics Inc. Common Stock stock for Q1 2020, down 21% quarter-over-quarter.
  • 14 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q1 2020 and 2 closed out, a net change of +12 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q1 2020 was BlackRock, an estimated $6.72M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q1 2020 was Omega Fund Management, an estimated $6.3M sold.

Based on aggregated 13F filings for Q1 2020.